Hepatitis A assay kit Procleix Parvo/HAV

sodiumparvovirusHAV

Procleix assays expand blood screening with a comprehensive NAT assay portfolio. The NAT solutions portfolio provides screening of: HIV-1, HIV-2, HCV, HBV, WNV, Parvovirus B19, HAV, HEV, Dengue Virus, Zika Virus, Babesia, and Plasmodium. Start Releasing Test Results Within 3.5 Hours When you need results as soon as possible, the Procleix system allows you to efficiently manage your workload. From a single sample, process up to four assays on one system at the same time First result within 3.5 hours, then additional run results every 5 minutes after Don't wait for your instrument to catch up with you—STATs immediately processed once loaded Reduce Costs The costs for recruiting donors and waste disposal are often overlooked. The Procleix assay portfolio helps blood banks reduce the cost of NAT screening. Single-tube processing means less solid waste to dispose of, fewer moving parts, and less maintenance Reduce hazardous liquid disposal costs – liquid waste can be poured down the drain Up to 24 months* shelf life means less lot release validation and easier inventory management *with the exception of the Procleix Plasmodium assay. Comprehensive Assay Menu The Procleix assay portfolio contains a comprehensive menu of assays for the current NAT testing needs around the world. An expanding assay menu Rapid response to emerging needs for blood safety worldwide Isothermal TMA technology eliminates the need for thermocycling, which is used in PCR Long shelf life and larger master lots lead to less variability in results Single-tube, highly sensitive detection of the parvovirus B19 DNA and hepatitis A virus RNA in blood and plasma donations.